https://www.contemporarypediatrics.com/view/fda-approves-first-gene-therapy-to-treat-pediatric-patients-with-duchenne-muscular-dystrophy
0
0
6/23/23 at 4:13pm
Organization
Contemporarypediatrics.com
Author
Joshua Fitch
The accelerated approval of delandistrogene moxeparvovec-rokl is “based on expression of Elevidys micro-dystrophin observed in patients treated with ELEVIDYS,” according to Sarepta Therapeutics.
Create an account
or login to join the discussion